Session » SLE – Etiology & Pathogenesis Poster I

Date: Monday, November 11, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1021

Anti-IFNAR Treatment Does Not Reverse Neuropsychiatric Disease in MRL/lpr Lupus Mice

9:00AM-11:00AM: Abstract Number: 1027

Characterization of Antibody Secreting Cells in Patients with Active Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1034

Circulating MicroRNAs as Potential Biomarkers for Monitoring the Response to In Vivo Treatment with Rituximab in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1038

Distinct Cell-bound Complement Activation Signatures Are Observed in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1030

DNA Methylation Changes Are Associated with Particulate Matter 2.5 Exposure in SLE Patients

9:00AM-11:00AM: Abstract Number: 1025

Dynamic Changes During SLE Flare Implicate Age-Associated B Cells and Altered T Follicular and Peripheral Helper Cell Responses in Disease Activity

9:00AM-11:00AM: Abstract Number: 1029

Epstein-Barr Virus Interleukin 10 in SLE Pathogenesis

9:00AM-11:00AM: Abstract Number: 1015

Evidence for Substantial Immune Activation in Asymptomatic ANA Positive Individuals

9:00AM-11:00AM: Abstract Number: 1035

Examining the Transcriptional Impact of Liganded ERα in the Inflammatory Milieu of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1031

Expanded Circulating Peripheral Helper T Cells Are Associated with B Cell Differentiation in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1016

Identification of Differentially Expressed Genes and Signaling Pathways in Systemic Lupus Erythematosus by Integrated Bioinformatics Analysis

9:00AM-11:00AM: Abstract Number: 1026

Interferon Lambda Promotes Age-Associated B Cells

9:00AM-11:00AM: Abstract Number: 1032

Lipocalin-2 Exacerbates Lupus Nephritis by Promoting Th1 Cell Differentiation

9:00AM-11:00AM: Abstract Number: 1028

Lupus Auto-antibodies Act as Positive Allosteric Modulators at GluN2A-containing NMDA Receptors to Induce Excitotoxicity and Spatial Memory Deficits

9:00AM-11:00AM: Abstract Number: 1024

Lysosome Defects in SLE Promote the Accumulation of Nuclear Antigens on the Surface of Hematopoietic Cells

9:00AM-11:00AM: Abstract Number: 1033

Mass Cytometric Immunophenotyping Highlights a Dysregulated T cell-B Cell Axis in Patients with New-onset Lupus

9:00AM-11:00AM: Abstract Number: 1039

Molecular Profiling Identifies Immunologic Subgroups and Informs Mechanism of Action of Baricitinib in SLE

9:00AM-11:00AM: Abstract Number: 1023

Neutrophils Are an Important Source of Microparticles in Lupus and Asymptomatic ANA+ Individuals

9:00AM-11:00AM: Abstract Number: 1020

NLRP12 Regulates Interferon-α Expression and Is a Biomarker for Disease Activity of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1018

Renal Single Cell Genomics Links Type II Interferon and Lupus Nephritis in African-Americans

9:00AM-11:00AM: Abstract Number: 1036

RNA Sequencing of PBMCs Reveals Estrogen-Mediated Upregulation of Micro-RNA Processing Machinery

9:00AM-11:00AM: Abstract Number: 1022

Single Cell Transcriptome Analysis of Circulating Plasmacytoid Dendritic Cells and Switched Memory B-cells in SLE Patients Reveals Transcriptional Subsets Within the Classical Cell Lineages

9:00AM-11:00AM: Abstract Number: 1017

The Integration of Genetic Data, Molecular Pathway Analysis and Differential Expression to Delineate the Impact of Ancestral Differences on Lupus

9:00AM-11:00AM: Abstract Number: 1019

Type I Interferon Levels Vary with Regional Ancestry in European-derived SLE Cohorts

9:00AM-11:00AM: Abstract Number: 1037

Urinary C3d Is a Good Marker for Monitoring Treatment Response After 3 Months of Induction Treatment in Patients with Biopsy Proven Lupus Nephritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].